Objectives: In this study, we examined the alteration of the G2 pathway in endometrial hyperplasia (EH) and endometrioid-type endometrial cancer (EC), and analyzed the relationship between the G2 pathway status and the p53 pathway status. Methods: A total of 103 cases (proliferative phase of the endometrium: 20, EH: 22, and endometrioid-type EC: 61 (I: 39, II: 5, III: 15, recurrence: 2)) were included in this study. We examined the ATM, chk2, CDC25C, cdc2, and cyclin B1 protein expression by immunohistochemistry. In 55 cases (EH: 15; EC: 40), we analyzed chk2 mutations by RT-PCR-SSCP. Results: There were no chk2 mutations in endometrial disease. Elevated or reduced expression rates of ATM, chk2, CDC25C, cdc2 and cyclin B1 were 4.5% (1/22), 0%, 0%, 0% and 4.5% (1/22) in EH and 3.3% (2/61), 4.9% (3/61), 13.1% (8/61), 9.8% (6/61) and 9.8% (6/61) in EC. Alteration of the G2 pathway was higher in EC (32.8%; 20/61) than in EH (9.1%; 2/22; p = 0.047). The G2 pathway was significantly higher in the altered p53 pathway group (48.4%; 15/31) than in the normal p53 pathway group (16.7%; 5/30) in EC (p = 0.0134). The altered p53 pathway tended to be related with the cdc2/cyclin B1 status (p = 0.0529). Conclusions: Alteration of the G2 pathway is thought to occur during carcinogenesis of the endometrium.

Keywords:
cdc2, CDC25C, chk2, Cyclin B1, Endometrial cancer, G2 pathway, p53
1.
Barakat RR, Grigsby PW, Sabbatini P, Zaino RJ: Corpus: Epithelial tumors; in Hoskins WJ, Perez CA, Young RC (eds): Principles and Practice of Gynecologic Oncology, ed 3. Baltimore, Williams & Wilkins, 2000, p 921.
2.
Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge RK, Barrett JC, Berchuck A: PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 1998;4:3005–3010.
3.
Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, Weng LP, Eng C: Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924–930.
4.
Furnari FB, Huang HJ, Cavenee WK: The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res 1998;58:5002–5008.
5.
Bruni P, Boccia A, Baldassarre G, Trapasso F, Santoro M, Chiappetta G, Fusco A, Viglietto G: PTEN expression is reduced in a subset of sporadic thyroid carcinomas: Evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene 2000;19:3146–3155.
6.
Tsuda H, Yamamoto K, Inoue T, Uchiyama I, Umesaki N: The role of p16-cyclinD/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial cancer. Br J Cancer 2000;82:675–682.
7.
Maeda K, Tsuda H, Hashiguchi Y, Yamamoto K, Inoue T, Ishiko O, Ogita S: Relationship between G1 pathway and estrogen receptor status in endometrioid-type endometrial cancer. Hum Pathol 2002;33:386–391.
8.
Matsuoka S, Huang M, Elledge SJ: Linkage of ATM to cell cycle regulation by the chk2 protein kinase. Science 1998;282:1893–1897.
9.
Chaturvedi P, Eng WK, Zhu Y, Mattern MR, Mishra R, Hurle MR, Zhang W, Annan RS, Lu K, Faucette LF, Scott GF, Li X, Carr SA, Johnson RK, Winkler JD, Zhoub BS: Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 1999;18:4047–4054.
10.
Walworth NC, Bernards R: rad-dependent response of the chk1-encoded protein kinase at the DNA damage checkpoint. Science 1996;271:353–356.
11.
Sanchez Y, Wong C, Thoma RS, Richman R, Wu Zhiqi, Piwnica-Worms H, Elledge S: Conservation of the Chk1 check point pathway in mammals: Linkage of DNA damage to Cdk regulation through Cdc25. Science 1997;277:1497–1501.
12.
Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS, Piwnica-Worms H: Mitotic and G2 check point control: Regulation of 14–3-3 protein binding by phosphorylation of cdc25c on serine-216. Science 1997;277:1501–1505.
13.
Russel P, Nurse P: The mitotic inducer nim1+ functions in a regulatory network of protein kinase homologs controlling the initiation of mitosis. Cell 1987;49:569–576.
14.
Booher RN, Holman PS, Fattaey A: Human Mytl is a cell cycle regulated kinase that inhibits Cdc2 but not Cdk2 activity. J Biol Chem 1997;272:22300–22306.
15.
Dunphy WG, Kumagai A: The cdc25 protein contains an intrinsic phosphatase activity. Cell 1991;67:189–196.
16.
Gautier J, Solomon MJ, Booher RN, Bazan JF, Kirschner MW: Cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2. Cell 1991;67:197–211.
17.
Sebastian B, Kakizuka A, Hunter A: Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15. Proc Natl Acad Sci USA 1993;K90:3521–3524.
18.
Semba S, Ouyang H, Han SY, Kato Y, Horii A: Analysis of the candidate target genes for mutation in microsatellite instability-positive cancers of the colorectum, stomach, and endometrium. Int J Oncol 2000;16:731–737.
19.
Haruki N, Saito H, Tatematsu Y, Konishi H, Harano T, Masuda A, Osada H, Fujii Y, Takahashi T: Histological type-selective, tumor-predominant expression of a novel chk1 isoform and infrequent in vivo somatic chk2 mutation in small cell lung cancer. Cancer Res 2000;60:4689–4692.
20.
Kimura K, Shinmura K, Yoshimura K, Shimizu K, Katai H, Beppu Y, Moriya H, Yokota J: Absence of germline CHK2 mutations in familial gastric cancer. Jpn J Cancer Res 2000;91:875–879.
21.
Hofmann WK, Miller CW, Tsukasaki K, Tavor S, Ikezoe T, Hoelzer D, Takeuchi S, Koeffler HP: Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodyplastic syndromes and acute myeloid leukemias. Leuk Res 2001;25:333–338.
22.
Aktas D, Arno MJ, Rassool F, Mufti GJ: Analysis of CHK2 in patients with myelodysplastic syndromes. Leuk Res 2002;26:985–987.
23.
Taylor WR, Stark GR: Regulation of the G2/M transition by p53. Oncogene 2001;20:1803–1815.
24.
Tsuda H, Kawabata M, Inoue K, Yamamoto K: Correlation between the abnormality of G1 pathway and status of estrogen receptor in endometrioid-type endometrial carcinoma. Proceedings ASCO, 2000, abstr 659.
25.
Shiozawa T, Xin L, Nikaido T, Fujii S: Immunohistochemical detection of cyclin A with reference to p53 expression in endometrial endometrioid carcinoma. Int J Gynecol Pathol 1997;16:348–353.
26.
Shiozawa T, Nikaido T, Shimizu M, Zhai Y, Fujii S: Immunohistochemical analysis of the expression of cdk4 and p16INK4 in human endometrioid-type endometrial carcinoma. Cancer 1997;80:2250–2256.
27.
Nikaido T, Li SF, Shiozawa T, Fujii S: Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas. Cancer 1996;78:1248–1253.
28.
Hernandez S, Hernandez L, Bea S, Pinyol M, Nayach I, Bellosillo B, Nadal A, Ferrer A, Fernandez PL, Montserrat E, Cardesa A, Campo E: cdc25a and the splicing variant cdc25b2, but not cdc25B1, -B3 or -C, are over-expressed in aggressive human non-Hodgkin’s lymphomas. Int J Cancer 2000;20:148–152.
29.
Wu W, Fan YH, Kemp BL, Walsh G, Mao L: Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res 1998;58:4082–4085.
30.
Kudo Y, Yasui W, Ue T, Yamamoto S, Yokozaki H, Nikai H, Tahara E: Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas. Jpn J Cancer Res 1997;88:947–952.
31.
Broggini M, Buraggi G, Brenna A, Riva L, Codegoni AM, Torri V, Lissoni AA, Mangioni C, D’lncalci M: Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. Anticancer Res 2000;20:4835–4840.
32.
Wang A, Yoshimi N, Ino N, Tanaka T, Mori H: Overexpression of cyclinB1 in human colorectal cancers. J Cancer Res Clin Oncol 1997;123:124–127.
33.
Murakami H, Furihata M, Ohtsuki Y, Ogoshi S: Determination of the prognostic significance of cyclinB1 overexpression in patients with esophageal squamous cell carcinoma. Virchows Arch 1999;434:153–158.
34.
Ito Y, Takeda T, Sakon M, Monden M, Tsujimoto M, Matsuura N: Expression and prognostic role of cyclin-dependent kinase 1(cdc2) in hepatocellular carcinoma. Oncology 2000;59:68–74.
35.
Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK, Mao L: Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 2000;60:4000–4004.
36.
Yamamoto H, Monden T, Ikeda K, Izawa H, Fukuda K, Fukunaga M, Tomita N, Shimano T, Shiozaki H, Monden M: Coexpression of cdk2/cdc2 and retinoblastoma gene products in colorectal cancer. Br J Cancer 1995;71:1231–1236.
37.
Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA: Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999;286:2528–2531.
38.
Angele S, Treilleux I, Taniere P, Martel-Planche G, Vuillaume M, Bailly C, Bremond A, Montesano R, Hall J: Abnormal expression of the ATM and TP53 genes in sporadic breast carcinomas. Clin Cancer Res 2000;6:3536–3544.
39.
Starostik P, Manshouri T, O’Brien S, Freireich E, Kantarjian H, Haidar M, Lerner S, Keating M, Albitar M: Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res 1998;58:4552–4557.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.